TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1547080

Group type: EXPERIMENTAL
Intervention: Angioscopy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 110
Study: 3518725

Group type: EXPERIMENTAL
Intervention: Ibopamine (SB-7505) for 10 days
Number of subjects: 42
Study: 29798823

Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular release (ACR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrodilatation (HD)
Number of subjects: 50
Study: 27472572

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Combination of Dexamethasone and Ondansetron
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Dexamethasone, Ondansetron, Combination
Number of subjects: 352
Study: 24149768

Group type: EXPERIMENTAL
Intervention: Experimental group (E; n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (C; n = 11)
Number of subjects: 23
Study: 22147661

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 59
Study: 20932179

Group type: EXPERIMENTAL
Intervention: Household salt iodine content measurement
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration measurement
Number of subjects: 639

Group type: COMPARATOR
Intervention: Comparison of UIC between genders
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Daily salt intake measurement
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: UIC classification according to WHO/ICCIDD/UNICEF
Number of subjects: 639
Study: 18390769

Group type: EXPERIMENTAL
Intervention: Men (intervention group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Women (control group)
Number of subjects: 34
Study: 18325757

Group type: EXPERIMENTAL
Intervention: Testosterone-in-adhesive matrix patch (4.8 mg testosterone daily, 2 patches of 60 cm2 every 48 hours)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Intramuscular testosterone enanthate injection (every 3 weeks)
Number of subjects: 224
Study: 14706764

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol and gestodene
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 11216754

Group type: EXPERIMENTAL
Intervention: Lexipafant 10 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lexipafant 100 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 150
Study: 9010144

Group type: EXPERIMENTAL
Intervention: Six months of oral anticoagulant therapy
Number of subjects: 227

Group type: COMPARATOR
Intervention: Indefinite oral anticoagulant therapy
Number of subjects: 227
Study: 7692778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 9
Study: 3321865

Group type: EXPERIMENTAL
Intervention: Vasopressin antagonist (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin) 10 micrograms/kg body weight
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study: 31553765

Group type: EXPERIMENTAL
Intervention: Ozone exposure at 120 ppb
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ozone exposure at 70 ppb
Number of subjects: 87

Group type: COMPARATOR
Intervention: Filtered air (0 ppb)
Number of subjects: 87
Study: 30397714

Group type: EXPERIMENTAL
Intervention: Knowledge assessment of dental hygienists regarding systemic diseases and oral health
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Confidence and comfort in managing patients with systemic conditions
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Agreement on the need for dental hygienists to be prepared to manage medically compromised patients
Number of subjects: 192
Study: 26955679

Group type: EXPERIMENTAL
Intervention: Jiakangling Capsule (JC) combined with reduction of 131I (50-80 microCi per gram of thyroid tissue) taken for one month after 131I treatment.
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Jiakangling Capsule (JC) combined with reduction of 131I.
Number of subjects: 387
Study: 24555788

Group type: EXPERIMENTAL
Intervention: Acupuncture at SP6
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture at GB39
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nonacupoint acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (SP6, GB39, Nonacupoint)
Number of subjects: 60
Study: 22895207

Group type: EXPERIMENTAL
Intervention: External cold and vibration stimulation via Buzzy
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 120
Study: 21073098

Group type: EXPERIMENTAL
Intervention: Early Active Motion (EAM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Early Passive Motion (EPM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 27
Study: 18201433

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (Inhaled Fluticasone Propionate)
Number of subjects: 12
Study: 15839852

Group type: EXPERIMENTAL
Intervention: Adenosine 80 microg kg(‐1) min(‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adenosine 120 microg kg(‐1) min(‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adenosine (both doses)
Number of subjects: 12
Study: 12442019

Group type: EXPERIMENTAL
Intervention: Tunneled catheters
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nontunneled catheters
Number of subjects: 98
Study: 9470002

Group type: EXPERIMENTAL
Intervention: L-Thyroxine (8 micrograms/kg birthweight per day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: L-Thyroxine
Number of subjects: 200
Study: 7666874

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study: 2505682

Group type: EXPERIMENTAL
Intervention: 5-FU + PSK (3 g/day for 4 weeks and 5-FU 150 mg/day for 4 weeks, 10 courses)
Number of subjects: 262

Group type: COMPARATOR
Intervention: 5-FU alone (for 4 weeks with alternate rest interval for 4 weeks)
Number of subjects: 262
Study: 1187976

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka mixed with a soft drink)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No alcohol (soft drink alone as placebo)
Number of subjects: 52
Study: 31872771

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine Clinical Practice (RCP)
Number of subjects: 0
Study: 29019167

Group type: EXPERIMENTAL
Intervention: Hybrid simulation (breast jacket + SP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (tabletop breast model)
Number of subjects: 82
Study: 27793547

Group type: EXPERIMENTAL
Intervention: Educational intervention (3 interactive workshops on cardiovascular disease prevention)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (information by mail)
Number of subjects: 320
Study: 26357419

Group type: EXPERIMENTAL
Intervention: 1.5 L daily of EVIAN water on top of usual intake for 50 days
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual lifestyle habits (Control)
Number of subjects: 65
Study: 23531324

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 295

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 295
Study: 21256670

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture (twice a week for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (sham-acupuncture, twice a week for 4 weeks)
Number of subjects: 90
Study: 19765497

Group type: EXPERIMENTAL
Intervention: Nurse practitioner (NP) lifestyle counseling with standardized computerized software program
Number of subjects: 457

Group type: COMPARATOR
Intervention: General practitioner usual care (GP-UC)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Nurse practitioner (NP) lifestyle counseling
Number of subjects: 457
Study: 17761230

Group type: EXPERIMENTAL
Intervention: DASH diet (rich in fruits, vegetables, and low-fat dairy products) at intermediate sodium level (2,300 mg/day)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control diet at intermediate sodium level (2,300 mg/day)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 354
Study: 15011426

Group type: EXPERIMENTAL
Intervention: Lockable CSE device (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lockable CSE device (Group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional CSE device (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lockable CSE device (Group II and III)
Number of subjects: 60
Study: 15669554

Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) and trimegestone (TMG 0.25 or 0.5 mg)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Estradiol and norethisterone acetate
Number of subjects: 487
Study: 11506836

Group type: EXPERIMENTAL
Intervention: OC-fluconazole
Number of subjects: 26

Group type: COMPARATOR
Intervention: OC-placebo
Number of subjects: 26
Study: 9242038

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study: 8294170

Group type: EXPERIMENTAL
Intervention: Ketoprofen 2.5% gel applied twice a day for seven days (250 mg per day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ketoprofen 2.5% gel
Number of subjects: 56
Study: 3327724

Group type: EXPERIMENTAL
Intervention: Aminophylline (1.5 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (Aminophylline and Placebo)
Number of subjects: 110
Study: 29402711

Group type: COMPARATOR
Intervention: Tamsulosin alone: 0.2 mg/d
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg/d plus celecoxib: 200 mg/d
Number of subjects: 310
Study: 27281374

Group type: EXPERIMENTAL
Intervention: Drug Attention Control Training Program (Drug‐ACTP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 48
Study: 25428341

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Granule (BHG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride dispersible tablet (Control)
Number of subjects: 62
Study: 23713299

Group type: EXPERIMENTAL
Intervention: Direct moxibustion at Sihua points (Geshu (BL 17) and Danshu (BL 19)), three moxa-cones once a day for ten days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy (Navelbine and cisplatin)
Number of subjects: 80
Study: 20626953

Group type: EXPERIMENTAL
Intervention: Passive consent
Number of subjects: 185

Group type: COMPARATOR
Intervention: Active consent
Number of subjects: 185
Study: 18378749

Group type: EXPERIMENTAL
Intervention: Surgery for stress urinary incontinence
Number of subjects: 655
Study: 16600816

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation at doses of 1.35, 2.7, or 4.05 g/d for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (no additional omega‐3 polyunsaturated fatty acids)
Number of subjects: 0
Study: 12560440

Group type: EXPERIMENTAL
Intervention: RT‐PCR positive for PSA
Number of subjects: 162

Group type: COMPARATOR
Intervention: RT‐PCR negative for PSA
Number of subjects: 162
Study: 10867111

Group type: EXPERIMENTAL
Intervention: R121919 (5-40 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R121919 (40-80 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R121919 (overall)
Number of subjects: 24
Study: 9263770

Group type: EXPERIMENTAL
Intervention: ACP*A gene frequency
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PGM1*2 gene frequency
Number of subjects: 140

Group type: COMPARATOR
Intervention: Comparison of ACP with other populations
Number of subjects: 140

Group type: COMPARATOR
Intervention: Comparison of PGM1 with other populations
Number of subjects: 140
Study: 1297878

Group type: EXPERIMENTAL
Intervention: Early physical trainings without coronary active agents
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physical exercises with antianginal drugs (first control group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Therapeutical exercises, graded walking, nitrates, beta-blockers, calcium antagonists (second control group)
Number of subjects: 51
Study: 6381170

Group type: EXPERIMENTAL
Intervention: Theocontin Continus tablets
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nuelin S.A.
Number of subjects: 25
Study: 30368939

Group type: EXPERIMENTAL
Intervention: 20 IU/kg VE
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 100 IU/kg VE
Number of subjects: 216

Group type: COMPARATOR
Intervention: 0 IU/kg VE
Number of subjects: 216

Group type: COMPARATOR
Intervention: Ageing corn diet
Number of subjects: 216
Study: 28646416

Group type: EXPERIMENTAL
Intervention: Combination treatment (solifenacin 5 mg plus mirabegron 25 mg for the first 4 weeks/50 mg for the last 8 weeks)
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Solifenacin 10 mg
Number of subjects: 2054
Study: 25885649

Group type: EXPERIMENTAL
Intervention: Subjective physical activity (assessed via the International Physical Activity Questionnaire; IPAQ)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Objective physical activity (accelerometry; GT3X)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Subjective moderate PA (IPAQ)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Subjective MVPA (IPAQ)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 68
Study: 23598181

Group type: EXPERIMENTAL
Intervention: Intervention (brief counselling from trained family doctors)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 272
Study: 21494790

Group type: EXPERIMENTAL
Intervention: Sulpiride (400 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19726226

Group type: EXPERIMENTAL
Intervention: Nadroparin (3800 IU anti-Xa once a day)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150
Study: 17803380

Group type: EXPERIMENTAL
Intervention: Diode laser followed by ultrasonic scaling (DL + US)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ultrasonic scaling alone (US)
Number of subjects: 22
Study: 15084619

Group type: EXPERIMENTAL
Intervention: High-dose sequential chemotherapy and autografting
Number of subjects: 70
Study: 12404273

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 299

Group type: COMPARATOR
Intervention: No estrogen replacement therapy (No ERT)
Number of subjects: 299
Study: 9633494

Group type: EXPERIMENTAL
Intervention: Endovascular technique (TPEG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 7823359

Group type: EXPERIMENTAL
Intervention: Intensive surveillance (n = 56)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine surveillance (n = 50)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Intensive surveillance (n = 23)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine surveillance (n = 20)
Number of subjects: 156
Study: 2195575

Group type: EXPERIMENTAL
Intervention: Isoproterenol-induced panic attacks (panicking patients)
Number of subjects: 115
Study: 350590

Group type: COMPARATOR
Intervention: β‐acetyl digoxin (D) 0.1, 0.2, 0.3, 0.4, 0.5 or 0.6 mg daily for 7 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: digitoxin (Dt) 0.04, 0.08, 0.12, or 0.16 mg daily for 7 days
Number of subjects: 120
Study: 7051985

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 223

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 223
Study: 30676487

Group type: EXPERIMENTAL
Intervention: Single 900mg oral dose of delafloxacin
Number of subjects: 460

Group type: COMPARATOR
Intervention: Single 250mg intramuscular ceftriaxone
Number of subjects: 460
Study: 28952914

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 0
Study: 26674122

Group type: EXPERIMENTAL
Intervention: Cognitive Vitality Training (CVT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Computerised cognitive training (CCT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Computerised cognitive training (CCT) and Cognitive Vitality Training (CVT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 74
Study: 25172875

Group type: EXPERIMENTAL
Intervention: Computerized insulin infusion program (CIIP)
Number of subjects: 210
Study: 22775976

Group type: COMPARATOR
Intervention: AZD1656 (7, 20, 40 or 80 mg) twice daily for 8 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: AZD1656 (15-45 mg) twice daily for 28 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21057411

Group type: EXPERIMENTAL
Intervention: Integrated long-term program of management at FEC
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine psychiatric services (control group)
Number of subjects: 114
Study: 17875625

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Unstructured support
Number of subjects: 11
Study: 15381116

Group type: EXPERIMENTAL
Intervention: ACE1 polymorphism in hypoxemic group
Number of subjects: 44

Group type: COMPARATOR
Intervention: ACE1 polymorphism in SARS cases
Number of subjects: 44
Study: 11380778

Group type: EXPERIMENTAL
Intervention: Gold alloy crowns cemented with zinc phosphate cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gold alloy crowns with manual burnishing technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pure titanium crowns cemented with zinc phosphate cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pure titanium crowns with manual burnishing technique
Number of subjects: 40
Study: 9121993

Group type: EXPERIMENTAL
Intervention: Biphasic active can (AC) (model 7219C system, Medtronic, Inc.)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Passive can (PC) (model 7219D system)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 304
Study: 8506191

Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg twice a day for 8 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg twice a day for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: nisoldipine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: nisoldipine and nifedipine
Number of subjects: 28
Study: 2965139

Group type: EXPERIMENTAL
Intervention: Aerosol procaterol hydrochloride at 5 micrograms per puff
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral procaterol hydrochloride at 25 micrograms
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 10
Study: 28211031

Group type: EXPERIMENTAL
Intervention: Higher proportion of female peers in the classroom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-achieving classroom
Number of subjects: 0

Group type: COMPARATOR
Intervention: Average classroom achievement
Number of subjects: 0
Study: 27145977

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (2 to 8 mg) delivered in low volumes (0.1 to 0.2 mL) using an Aptar Unit‐Dose device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular naloxone (0.4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal naloxone (4 mg) delivered in a single device (0.1 mL)
Number of subjects: 0
Study: 24675370

Group type: EXPERIMENTAL
Intervention: IA injection of 30IU of BoNT A
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22617279

Group type: EXPERIMENTAL
Intervention: 5 mg per day of lactotripeptides for 3 months
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 50 mg per day of lactotripeptides for 3 months
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo milk drink without lactotripeptides
Number of subjects: 89
Study: 19117242

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle sampling with suction
Number of subjects: 52

Group type: COMPARATOR
Intervention: EUS-guided fine-needle sampling without suction
Number of subjects: 52
Study: 17162048

Group type: EXPERIMENTAL
Intervention: Tension-Free Vaginal Tape
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transobturator Vaginal Tape Inside-Out
Number of subjects: 120
Study: 16381203

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cervical fusion
Number of subjects: 46
Study: 11593943

Group type: EXPERIMENTAL
Intervention: Mortality salience induction
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control induction
Number of subjects: 240
Study: 9722212

Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (UW group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bretschneider's Histidine‐Tryptophan‐Ketoglutarate solution (HTK group)
Number of subjects: 21
Study: 8067218

Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine/morphine for 48 h postoperatively plus oral piroxicam
Number of subjects: 42

Group type: COMPARATOR
Intervention: General anaesthesia followed by a conventional intramuscular opioid and acetaminophen regimen
Number of subjects: 42
Study: 3044474

Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 22